The Connectivity Map: a new tool for biomedical research
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The ultimate objective of biomedical research is to connect human diseases with the genes that underlie them and drugs that treat them. But this remains a daunting task, and even the most inspired researchers still have to resort to laborious screens of genetic or chemical libraries. What if at least some parts of this screening process could be systematized and centralized? And hits found and hypotheses generated with something resembling an internet search engine? These are the questions the Connectivity Map project set out to answer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they do not support complex molecular readouts such as transcriptome profiling, which is one of the most comprehensive and informative measures of cellular response 5 .”
From Pooled CRISPR screening with single-cell transcriptome readout. (2017) · cites this paper as [5]
In the citing paper
“This tool allowed researchers to investigate genome-wide effects of GHK and establish that GHK-Cu is able to up- and down-regulate a significant number of human genes.”
From Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (2018) · cites this paper as [3]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“) to rationality (chronic myeloid leukaemia–BCR-ABL–imatini”
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Cited by
Items 101–200 of 984
Shameer, K., Readhead, B., & Dudley, J. T. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150112103510 · Cited by 102
“org/ cmap/) [62-64] and LINCS (http://www.”
Redaelli, S., Ceccon, M., Zappa, M., Sharma, G. G., Mastini, C., Mauri, M., Nigoghossian, M., Massimino, L., Cordani, N., Farina, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1867 · Cited by 94
“Analysis of gene expression data by connectivity map tool (31) indicated two AKT inhibitors among the three top negatively connected perturbagens, suggesting that AKT inhibition may lead to reversal of the biological state encoded in the query signature (i.”
MethodLean Big Data integration in systems biology and systems pharmacology
Ma’ayan, A., Rouillard, A. D., Clark, N. R., Wang, Z., Duan, Q., & Kou, Y. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.001 · Cited by 91
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
Laverdière, I., Boileau, M., Neumann, A. L., Frison, H., Mitchell, A., Ng, S., Wang, J. C. Y., Minden, M. D., & Eppert, K. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0087-2 · Cited by 90
Bruni, G. N., Lakhani, P., & Kokel, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00153 · Cited by 96
Stratmann, A. T., Fecher, D., Wangorsch, G., Göttlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G., & Nietzer, S. L. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.009 · Cited by 86
“Drug responses do not mostly rely on a single specific target, but on multiple effects of this drug on the signaling network (Lamb, 2007).”
BackgroundLee, H. S., Bae, T., Lee, J.-H., Kim, D. G., Oh, Y. S., Jang, Y., Kim, J.-T., Lee, J.-J., Innocenti, A., Supuran, C. T., et al. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-80 · Cited by 87
“For instance, drug repositioning approaches have incorporated in silico approaches for analyzing large data sets such as gene expression profiles [4,5], literature mining [6], chemical similarity [7], side-effect similarity [8], disease-drug network [9], pathway-based disease network [10], and…”
BackgroundThioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide
Johannessen, T.-C. A., Hasan‐Olive, M. M., Zhu, H., Denisova, O. V., Grudic, A., Latif, A., Saed, H. S., Varughese, J. K., Røsland, G. V., Yang, N., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31912 · Cited by 92
“This list of genes was integrated into ConnectivityMap build 02 (Cmap).(13,14) Cmap is an initiative by the Broad Institute of MIT and Harvard, where the effects of 1,309 small molecules on several cultured human cells have been systematically examined, resulting in a collection of more than 7,000 expression profiles…”
MethodComputational Drug Repurposing: Current Trends
Karaman, B., & Sippl, W. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530100332 · Cited by 95
Rho, S. B., Kim, B.-R., & Kang, S. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.10.003 · Cited by 91
“Recently, a gene-expression-based screening tool for polypharmacology drug discovery was introduced [29,30].”
BackgroundMethodAn in-depth snake venom proteopeptidome characterization: Benchmarking Bothrops jararaca
Nicolau, C. A., Carvalho, P. C., Junqueira-de-Azevedo, I. L. M., Teixeira‐Ferreira, A., Junqueira, M., Perales, J., Neves‐Ferreira, A. G. C., & Valente, R. H. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.06.029 · Cited by 88
Abelin, J. G., Patel, J., Lu, X., Feeney, C. M., Fagbami, L., Creech, A. L., Hu, R., Lam, D., Davison, D., Pino, L., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058354 · Cited by 87
“Thus, the assay espouses the “Connectivity Map” principle of using molecular profiles as an abstract means of associating cellular phenotypes (3, 4).”
BackgroundMethodTranslational Bioinformatics: Past, Present, and Future
Tenenbaum, J. D. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.01.003 · Cited by 94
“One of the prominent early examples of a computational approach to drug repositioning was the Broad Institute’s Connectivity Map (CMap) [36].”
BackgroundStumpel, D. J. P. M., Schneider, P., Seslija, L., Osaki, H., Williams, O., Pieters, R., & Stam, R. W. (2011) · Leukemia · doi:10.1038/leu.2011.278 · Cited by 95
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 87
“In order to deduce possible new indications, each of the signatures was then compared against the reference drug signatures available through the connectivity map [64, 65].”
BackgroundMethodRole of Patient-Derived Models of Cancer in Translational Oncology
Idrisova, K., Simon, H., & Gomzikova, M. O. (2022) · Cancers · doi:10.3390/cancers15010139 · Cited by 92
“Later, pharmacogenomics datasets such as Connectivity Map [10], the Sanger/Massachusetts General Hospital Genomics of Drug Sensitivity in Cancer (GDSC) [11], the Broad/Novartis Cancer Cell Line Encyclopedia (CCLE) [12], the Broad Cancer Therapeutics Response Portal (CTRP) [13] were created.”
BackgroundFang, H., Zeng, H., Lin, L.-M., Chen, X., Shen, X., Fu, P., Lv, C., Liu, Q., Liu, R., Zhang, W., et al. (2017) · Scientific Reports · doi:10.1038/srep43632 · Cited by 93
Explainable Artificial Intelligence: A Perspective on Drug Discovery
Qadri, Y. A., Shaikh, S., Ahmad, K., Choi, I., Kim, S. W., & Vasilakos, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091119 · Cited by 97
“Drug-centric techniques seek similarities in molecular action between drugs to identify new potential applications [131].”
Khunsriraksakul, C., Li, Q., Markus, H., Patrick, M. T., Sauteraud, R., McGuire, D., Wang, X., Wang, C., Wang, L., Chen, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36306-5 · Cited by 88
Kinaret, P., Serra, A., Federico, A., Kohonen, P. J., Nymark, P. E. H., Liampa, I., Ha, M. K., Choi, J., Jagiełło, K., Sanabria, N. M., et al. (2020) · Nanomaterials · doi:10.3390/nano10040750 · Cited by 81
“For example, the L1000 (Library of Integrated Network-Based Cellular Signatures 1000) platform that is used in the LINCS CMAP database uses flow cytometry and labeled beads [124].”
BackgroundInfluentialHassane, D. C., Sen, S., Minhajuddin, M., Rossi, R. M., Corbett, C. A., Balys, M. M., Wei, L., Crooks, P. A., Guzmán, M. L., & Jordan, C. T. (2010) · Blood · doi:10.1182/blood-2010-04-278044 · Cited by 81
Open Source Bayesian Models. 2. Mining a “Big Dataset” To Create and Validate Models with ChEMBL
Clark, A. M., & Ekins, S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00144 · Cited by 77
Prediction of disease–gene–drug relationships following a differential network analysis
Zickenrott, S., Angarica, V. E., Upadhyaya, B. B., & del Sol, A. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.393 · Cited by 75
Zhang, L., Kang, W., Lu, X., Ma, S., Dong, L., & Zou, B. (2018) · Gene · doi:10.1016/j.gene.2018.09.040 · Cited by 76
Matheny, C. J., Wei, M. C., Bassik, M. C., Donnelly, A. J., Kampmann, M., Iwasaki, M., Piloto, O., Solow-Cordero, D. E., Bouley, D. M., Rau, R., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.014 · Cited by 74
Stepping into the omics era: Opportunities and challenges for biomaterials science and engineering
Gröen, N., Güvendiren, M., RABITZ, H. A., Welsh, W. J., Kohn, J., & de Boer, J. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.02.015 · Cited by 83
“An illustrative example of convergence of multiple omics approaches is the Connectivity Map [62,63].”
BackgroundNiculescu, A. B., Le-Niculescu, H., Roseberry, K., Wang, S., Hart, J., Kaur, A., Robertson, H., Jones, T., Strasburger, A., Williams, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0602-2 · Cited by 75
Transcriptomics in Toxicogenomics, Part III: Data Modelling for Risk Assessment
Serra, A., Fratello, M., Cattelani, L., Liampa, I., Melagraki, G., Kohonen, P. J., Nymark, P. E. H., Federico, A., Kinaret, P., Jagiełło, K., et al. (2020) · Nanomaterials · doi:10.3390/nano10040708 · Cited by 78
“The Predictive Toxicogenomics Space (PTGS) scoring concept tool is based on modules derived from Latent Dirichlet Allocation (LDA) probabilistic component model analyses of the entire CMAP dataset [73] of over 1300 chemicals and drugs.”
Sandor, C., Robertson, P., Lang, C., Heger, A., Booth, H., Vowles, J., Witty, L., Bowden, R., Hu, M., Cowley, S. A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw412 · Cited by 74
“Given a disease-associated transcriptomic profile, compounds that provoke a correlated profile may provide insights into disease-relevant processes or new disease models, while compounds that provoke an anti-correlated response may themselves be of therapeutic value or provide lead to identifying new therapies (29,30).”
BackgroundHuang, T., Cui, W., Hu, L., Feng, K., Li, Y., & Cai, Y. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008126 · Cited by 76
“But it couldn’t systematically research drug response, because the reference collection of gene-expression profiles in Connectivity Map were from cultured human cells treated with bioactive small molecules and most cells were cancer cell lines.”
MethodInfluentialGlioblastoma: Imaging Genomic Mapping Reveals Sex-specific Oncogenic Associations of Cell Death
Colen, R. R., Wang, J., Singh, S. K., Gutman, D. A., & Zinn, P. O. (2014) · Radiology · doi:10.1148/radiol.14141800 · Cited by 77
Vidović, D., Koleti, A., & Schürer, S. C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00342 · Cited by 86
“In particular in the case of transcriptional pro-files, which have been related to disease phenotypes and models thereof (Lamb, 2007), these findings appear to support the feasibility of phenotypic lead optimization and utility of phenotypic structure-activity-relationships for drug development.”
BackgroundcanSAR: updated cancer research and drug discovery knowledgebase
Bulusu, K. C., Tym, J. E., Coker, E. A., Schierz, A. C., & Al-Lazikani, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1182 · Cited by 72
Recent advances in drug repurposing using machine learning
Urbina, F., Puhl, A. C., & Ekins, S. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.06.001 · Cited by 82
Soo, H. C., Chung, F. F., Lim, K., Yap, V. A., Bradshaw, T. D., Hii, L., Tan, S.-H., See, S.-J., Tan, Y.-F., Leong, C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170551 · Cited by 73
“Next, we queried Cud C-response gene signature against the Connectivity Map (CMap) resource [26, 27].”
MethodGene Expression Signature-Based Screening Identifies New Broadly Effective Influenza A Antivirals
Josset, L., Textoris, J., Loriod, B., Ferraris, O., Moulés, V., Lina, B., Nguyen, C., Diaz, J., & Rosa‐Calatrava, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013169 · Cited by 77
“The Connectivity Map is a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules [13].”
BackgroundMethodInfluentialA network-based approach to identify deregulated pathways and drug effects in metabolic syndrome
Misselbeck, K., Parolo, S., Lorenzini, F., Savoca, V., Leonardelli, L., Bora, P., Morine, M. J., Mione, M., Domenici, E., & Priami, C. (2019) · Nature Communications · doi:10.1038/s41467-019-13208-z · Cited by 75
A Survey on the Computational Approaches to Identify Drug Targets in the Postgenomic Era
Dai, Y.-F., & Zhao, X.-M. (2015) · BioMed Research International · doi:10.1155/2015/239654 · Cited by 76
“The new indications of some drugs were discovered based on the alignment of drug signatures with the assumption that drugs with similar signatures may have similar therapeutic effects [12].”
BackgroundMolecular signature of anastasis for reversal of apoptosis
Tang, H. M., Talbot, C. C., Fung, M. C., & Tang, H. L. (2017) · F1000Research · doi:10.12688/f1000research.10568.2 · Cited by 81
Predicting protein targets for drug-like compounds using transcriptomics
Pabon, N. A., Xia, Y., Estabrooks, S. K., Ye, Z., Herbrand, A. K., Süß, E., Biondi, R. M., Assimon, V. A., Gestwicki, J. E., Brodsky, J. L., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006651 · Cited by 79
“More recently, a new paradigm for predicting molecular interactions using cellular gene expression profiles has emerged [22-24].”
BackgroundCoombs, G. S., Schmitt, A. A., Canning, C. A., Alok, A., Low, I. C. C., Banerjee, N., Kaur, S., Utomo, V, Jones, C. M., Pervaiz, S., et al. (2012) · Oncogene · doi:10.1038/onc.2011.228 · Cited by 68
“Full details of the Connectivity Map data set and analytics are provided elsewhere (Lamb et al., 2006; Lamb, 2007).”
MethodInfluentialBarlow, D. J., Buriani, A., Ehrman, T. M., Bosisio, E., Eberini, I., & Hylands, P. J. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.01.041 · Cited by 69
“CMAP is a database used for the identification of functional connections between drugs, genes and diseases (Lamb, 2007) .”
BackgroundPizzorno, A., Terrier, O., de Lamballerie, C. N., Julien, T., Padey, B., Traversier, A., Roche, M., Hamelin, M., Rhéaume, C., Croze, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00060 · Cited by 72
“HG-U133plus2 probesets were mapped to the U133A probesets using the Ensembl BioMarts online tool (36, 37), and connectivity scores and p-values were obtained using the CMAP algorithm (19, 20).”
BackgroundMethodTarkhov, A. E., Alla, R., Ayyadevara, S., Pyatnitskiy, M., Menshikov, L. I., Shmookler Reis, R. J., & Fedichev, P. O. (2019) · Scientific Reports · doi:10.1038/s41598-019-43075-z · Cited by 65
Artificial intelligence in the early stages of drug discovery
Cavasotto, C. N., & Di Filippo, J. I. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108730 · Cited by 65
Protein localization vector propagation: a method for improving the accuracy of drug repositioning
Yeu, Y., Yoon, Y., & Park, S. (2015) · Molecular BioSystems · doi:10.1039/c5mb00306g · Cited by 72
Reka, A. K., Kuick, R. D., Kurapati, H., Standiford, T. J., Omenn, G. S., & Keshamouni, V. G. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822adfb0 · Cited by 72
A systematic approach to orient the human protein–protein interaction network
Silverbush, D., & Sharan, R. (2019) · Nature Communications · doi:10.1038/s41467-019-10887-6 · Cited by 73
Machine learning prediction of oncology drug targets based on protein and network properties
Dezső, Z., & Ceccarelli, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3442-9 · Cited by 64
Ashton, J. M., Balys, M., Neering, S. J., Hassane, D. C., Cowley, G., Root, D. E., Miller, P. G., Ebert, B. L., McMurray, H. R., Land, H., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.024 · Cited by 68
“To test this concept using pharmacological agents we utilized the Broad Institute’s Connectivity Map (CMAP) database (Lamb, 2007; Lamb et al., 2006) to identify compounds that reverse the aberrant expression of CRGs observed in leukemia cells.”
MethodDeBi: Discovering Differentially Expressed Biclusters using a Frequent Itemset Approach
Harmancı, A. S., & Vingron, M. (2011) · Algorithms for Molecular Biology · doi:10.1186/1748-7188-6-18 · Cited by 75
Network based elucidation of drug response: from modulators to targets
Iorio, F., Saez-Rodriguez, J., & Bernardo, D. D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-139 · Cited by 64
“In this work, the authors also proposed a non parametric method based on the Kolmogorov-Smirnoff statistic [48] to find connections between a predefined gene signature and the gene expression profiles in the cMap [49].”
MethodSu, Y., Tang, W., Cheng, Y., Sia, P., Huang, C.-C. S., Lee, Y., Jiang, H.-Y., Wu, M., Lai, I., Lee, J.-W., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.012 · Cited by 70
“[13,14], and recently validated by Sirota et al.”
MethodVilar, E., Mukherjee, B., Kuick, R., Raskin, L., Misek, D. E., Taylor, J. M. G., Giordano, T. J., Hanash, S. M., Fearon, E. R., Rennert, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2432 · Cited by 66
Comess, K. M., McLoughlin, S. M., Oyer, J. A., Richardson, P. L., Stöckmann, H., Vasudevan, A., & Warder, S. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01921 · Cited by 71
Signature-based approaches for informed drug repurposing: targeting CNS disorders
Shukla, R., Henkel, N., Alganem, K., Hamoud, A.-R. A., Reigle, J. K., Alnafisah, R. S., Eby, H., Imami, A. S., Creeden, J. F., Miruzzi, S. A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0752-6 · Cited by 71
Shigemizu, D., Hu, Z., Hung, J., Huang, C. L., Wang, Y., & DeLisi, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002347 · Cited by 70
“As with other approaches [14,15,16] we utilize two databases: the Connectivity Map (CMAP) which provides information on expressed genes in cancer cell lines perturbed by bioactive compounds [6,14], and the Gene Expression Omnibus (GEO) [17], which stores transcript levels for various cancers.”
BackgroundMethodYang, J., Peng, S., Zhang, B., Houten, S. M., Schadt, E. E., Zhu, J., Suh, Y., & Tu, Z. (2019) · GeroScience · doi:10.1007/s11357-019-00106-x · Cited by 73
“A promising area under active development is based on the concept of Connectivity Map (CMap) (Lamb 2007), which uses compound perturbation-induced gene expression changes to identify drug candidates for treating human diseases (Iorio et al.”
BackgroundMethodInfluentialHuang, Y., Yeh, H., & Soo, V. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-s3-s4 · Cited by 67
“We compare our method with the previous state-of-theart Cmap project to evaluate the performance [10].”
BackgroundResultLaenen, G., Thorrez, L., Börnigen, D., & Moreau, Y. (2013) · Molecular BioSystems · doi:10.1039/c3mb25438k · Cited by 71
Guedj, F., Pennings, J. L., Massingham, L. J., Wick, H. C., Siegel, A. E., Tantravahi, U., & Bianchi, D. W. (2016) · Scientific Reports · doi:10.1038/srep32353 · Cited by 58
In focus: MLL-rearranged leukemia
de Boer, J., Walf-Vorderwülbecke, V., & Williams, O. (2013) · Leukemia · doi:10.1038/leu.2013.78 · Cited by 70
IDENTIFICATION OF DISCRIMINATING BIOMARKERS FOR HUMAN DISEASE USING INTEGRATIVE NETWORK BIOLOGY
DUDLEY, J. T., & BUTTE, A. J. (2008) · Biocomputing 2009 · doi:10.1142/9789812836939_0004 · Cited by 62
A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds
He, B., Hou, F., Ren, C., Bing, P., & Xiangzuo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.711225 · Cited by 60
“…Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), The Cancer Genome Atlas (TCGA, http://tcga-data.nci.nih.gov/ tcga/tcgaHome2.jsp), Gene Expression Database (GXD, http:// (85), which contains more than 6100 gene expression pro fi les induced by more than 1300 compounds in four cell lines.”
BackgroundDaves, M. H., Hilsenbeck, S. G., Lau, C. C., & Man, T. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-56 · Cited by 68
“signature, and as a result potentially reverse the metastatic phenotype [51,52].”
BackgroundProbiotics: a proactive approach to health. A symposium report
Thomas, L. V., Suzuki, K., & Zhao, J. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515004043 · Cited by 59
“lished significant correlation of responses to probiotics with responses measured for pharmaceutical drugs((11)).”
BackgroundVan Vleet, T. R., Liguori, M. J., Lynch, III, Rao, M., & Warder, S. (2019) · SLAS Discovery · doi:10.1177/2472555218799713 · Cited by 59
Zheng, W., Wu, J., Gu, J., Weng, H., Wang, J., Wang, T., Liang, X., & Cao, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00147 · Cited by 67
“org/cmap/, Update September 12, 2017) (Lamb et al., 2006; Lamb, 2007).”
MethodJiang, R., Su, G., Chen, X., Chen, S., Li, Q., Xie, B., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.039 · Cited by 64
Decoding Connectivity Map-based drug repurposing for oncotherapy
Zhao, Y., Chen, X., Chen, J., & Qi, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad142 · Cited by 67
Josset, L., Zeng, H., Kelly, S. M., Tumpey, T. M., & Katze, M. G. (2014) · mBio · doi:10.1128/mbio.01102-13 · Cited by 63
“To confirm whether drugs identified in IPA induce signatures opposite to those induced by IAVs, we used the publicly available Connectivity Map (Cmap) database (build 02) (45).”
MethodChoi, Y. E., Battelli, C., Watson, J., Liu, J. F., Curtis, J. D., Morse, A., Matulonis, U. A., Chowdhury, D., & Konstantinopoulos, P. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1929 · Cited by 63
“In order to identify candidate agents that may directly or indirectly inhibit HR, we used the Connectivity Map, a reference collection of gene expression signatures that have been generated by exposing cultured human cell lines to a variety of small molecule drugs[12, 13].”
MethodDrugSig: A resource for computational drug repositioning utilizing gene expression signatures
Wu, H., Huang, J., Zhong, Y., & Huang, Q. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177743 · Cited by 60
Newman, J. H., Holt, T. N., Hedges, L. K., Womack, B., Memon, S. S., Willers, E. D., Wheeler, L. A., Phillips, J. A., & Hamid, R. (2011) · Pulmonary Circulation · doi:10.4103/2045-8932.93545 · Cited by 76
“Gene set enrichment and Ingenuity map analyses were performed to further re ine the data.[16-19] Collectively, the results of this study provide molecular and cellular observations in possible genes of interest in HAPH leading to brisket disease.”
ResultVasavda, C., Xu, R., Liew, J., Kothari, R., Dhindsa, R. S., Semenza, E. R., Paul, B. D., Green, D. P., Sabbagh, M. F., Shin, J. Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo5633 · Cited by 60
Hsp90 Modulation for the Treatment of Alzheimer’s Disease
Zhao, H., Michaelis, M. L., & Blagg, B. S. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00001-5 · Cited by 63
Liu, T., Hsieh, Y., Chou, C.-J., & Yang, P. (2018) · Royal Society Open Science · doi:10.1098/rsos.181321 · Cited by 60
On the Variable Ordering in Subgraph Isomorphism Algorithms
Bonnici, V., & Giugno, R. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2515595 · Cited by 62
“Well-known examples are protein-protein interaction [1], [2], gene-regulatory [3], [4], [5], [6], drugeffect [7], [8], [9], [10], and disease correlation [11], [12], [13] networks.”
In silico models in drug development: where we are
Piñero, J., Furlong, L. I., & Sanz, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.007 · Cited by 65
“The US Broad Institute Connectivity Map [117,118] contains thousands of gene expression profiles of most FDA approved drugs tested in multiple cell types.”
BackgroundFederico, A., Serra, A., Ha, M. K., Kohonen, P. J., Choi, J., Liampa, I., Nymark, P. E. H., Sanabria, N. M., Cattelani, L., Fratello, M., et al. (2020) · Nanomaterials · doi:10.3390/nano10050903 · Cited by 62
DMAP: a connectivity map database to enable identification of novel drug repositioning candidates
Huang, H., Nguyen, T., Ibrahim, S., Shantharam, S., Yue, Z., & Chen, J. Y. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s13-s4 · Cited by 55
“Previous efforts [2,3,9,10] on pairing the expression of drugs and diseases mainly rely on experimental connectivity map.”
BackgroundJoo, M., Park, A., Kim, K., Son, W., Lee, H. S., Lim, G., Lee, J., Lee, D. H., An, J., Kim, J. H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246276 · Cited by 67
“When gene expression (equivalently, transcriptomics) profiles of two drugs are similar to each other, it is assumed that drug response to the specific drugs is also similar [14,15].”
BackgroundManfrini, N., Mancino, M., Miluzio, A., Oliveto, S., Balestra, M., Calamita, P., Alfieri, R. R., Rossi, R. L., Sassoé‐Pognetto, M., Salio, C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1357 · Cited by 58
“An unbiased search for potential sensitivities of FAM46Cexpressing cells, by connectivity map analysis (46), also predicted a potential sensitivity to sphingosine kinase inhibitors.”
BackgroundPathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics
Lemus, E. H., & Martínez-García, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.605680 · Cited by 61
“Startingwithhighthroughput,highlycuratedinformation from the CMAP (6), they applied machine learning tools (at that timeinthestateoftheart),discoverednoveldysregulatedpathways, in lung adenocarcinoma, fi nd key genes involved, look up for FDA approved targets.”
BackgroundMethodJafari, M., Wang, Y., Amiryousefi, A., & Tang, J. P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01319 · Cited by 62
“…Barneh et al., 2016; Chen et al., 2018), drug-target (Barneh et al., 2016), protein-cell localization (Mirzaei Mehrabad et al., 2018), drug-disease (Lamb, 2007) and drug-side effect associations (Luo et al., 2014), as well as associations at the patient level including patient-drug interactions…”
BackgroundMicroneedle-Mediated Delivery of Copper Peptide Through Skin
Li, H., Low, Y. S. J., Chong, H. P., Zin, M. T., Lee, C., Li, B., Leolukman, M., & Kang, L. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1652-z · Cited by 62
On the Path to Seeking Novel Radiosensitizers
Katz, D., Ito, E., & Liu, F. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.002 · Cited by 63
A network biology model of micronutrient related health
van Ommen, B., Fairweather-Tait, S., Freidig, A., Kardinaal, A., Scalbert, A., & Wopereis, S. (2008) · British Journal of Nutrition · doi:10.1017/s0007114508006922 · Cited by 56
“Similar concepts have been described for diseases and drug action (37,38) .”
Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis
Singh, M., Venugopal, C., Tokár, T., McFarlane, N., Subapanditha, M., Qazi, M. A., Bakhshinyan, D., Vora, P., Murty, N. K., Jurišica, I., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1022 · Cited by 60
Hajjo, R., Setola, V., Roth, B. L., & Tropsha, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2011657 · Cited by 56
“However, Lamb and colleagues 33;34 indicated that the nonconsistent scoring of different instances of the same chemical may represent either (1) a cellular-context dependent difference in activity, (2) a concentration-discriminated effect, or (3) poor reproducibility between replicates.”
BackgroundMethodInfluentialJadamba, E., & Shin, M. (2016) · BioMed Research International · doi:10.1155/2016/7147039 · Cited by 61
“For example, the Connectivity Map (CMap) [6, 7] project is exploring the effects of a large number of FDA-approved chemicals (1309 drugs) on gene expression, and these effects are measured in four different cell lines, allowing researchers to analyze the different expression patterns of drug’s target genes.”
BackgroundGeNets: a unified web platform for network-based genomic analyses
Li, T., Kim, A., Rosenbluh, J., Horn, H., Greenfeld, L., An, D., Zimmer, A., Liberzon, A., Bistline, J., Natoli, T., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0039-6 · Cited by 55
“Below is the distribution of pairwise Jaccard Index in the resulting 853 pathways, where 99.1% of pathway pairs have Jaccard Index <=0.15 and 93.3% have a Jaccard Index <= 0.05.”
InfluentialIn silico drug repositioning: from large-scale transcriptome data to therapeutics
Kwon, O., Kim, W., Cha, H., & Lee, H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01176-3 · Cited by 59
“Thus, when prior information on drugs is lacking, gene signature-based methods are the most cost-effective approach for elucidating the MOA (Lamb et al. 2006; Lamb 2007).”
BackgroundMethodGao, Y., Kim, S., Lee, Y., & Lee, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225601 · Cited by 57
“Golub’s group at the Broad Institute (Boston, MA, USA), and catalogs transcriptome data from cultured cells treated individually with small molecules (Figure 1C) [12,13].”
BackgroundDrug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Morris, R., Ali, R., & Cheng, F. (2024) · Current Drug Targets · doi:10.2174/0113894501290296240327081624 · Cited by 60
Acute myelogenous leukemia stem cells: From Bench to Bedside
Rico, J. F., Hassane, D. C., & Guzmán, M. L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.034 · Cited by 56
“Connectivity Map [67–69].”
The p53 Family Protein p73 Provides New Insights into Cancer Chemosensitivity and Targeting
Lunghi, P., Costanzo, A., Mazzera, L., Rizzoli, V., Levrero, M., & Bonati, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1229 · Cited by 54
Kosaka, T., Nagamatsu, G., Saito, S., Oya, M., Suda, T., & Horimoto, K. (2013) · Cancer Science · doi:10.1111/cas.12183 · Cited by 53
Ryan, N., Chorley, B. N., Tice, R. R., Judson, R., & Corton, J. C. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw026 · Cited by 52
“Although the full impact of this effort on the field of chemical genomics is yet to be determined, the LINCS project was derived in part from an earlier project called the Connectivity Map (CMAP) in which a collection of genome-wide transcriptional expression data was collected from cultured human cells treated with a…”
MethodInfluentialBoran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 56
“8,9,20,22,60,61 Abbreviations: shRNA, short hairpin RNA; SILAC, stable isotope labeling by amino acids in cell culture; siRNA, small interfering RNA.”
Background
Metadata
- Authors
- Lamb, J.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lamb, Justin
- Venue
- Nature Reviews Cancer
- Published
- 2007-01
- Volume
- 7
- Issue
- 1
- Pages
- 54-60
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2029980980
- Semantic Scholar
- d1610ee5045d33be16a9a72a514fea537ba46306
- Cited by
- 945
- References
- 66
- Citations by year
- 2026: 11 · 2025: 29 · 2024: 75 · 2023: 54 · 2022: 56 · 2021: 100 · 2020: 79 · 2019: 64 · 2018: 60 · 2017: 52 · 2016: 58 · 2015: 57 · 2014: 42 · 2013: 49 · 2012: 56
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Broad Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- Connectivity Map, gene-disease association, drug repurposing, gene expression profiling, cancer research, drug discovery
- MeSH terms
- Algorithms, Animals, Gene Expression Regulation, Humans, Information Services, Models, Biological, Models, Genetic, Neoplasms, Phenotype, Software, Information Storage and Retrieval, Genome, Computational Biology, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.